14 studies found for:    NY-ESO-1/LAGE-1
Show Display Options
Rank Status Study
1 Completed Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine
2 Recruiting Autologous T Cells Expressing Enhanced TCRs Specific for NYESO-1/LAGE in Patients With Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Biological: T cells
3 Completed NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
Conditions: Prostate Cancer;   Bladder Cancer;   Non-Small Cell Lung Cancer;   Esophageal Cancer;   Sarcoma
Intervention: Biological: NY-ESO-1 plasmid DNA Cancer Vaccine
4 Completed Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
Condition: Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Intervention: Other: Data acquisition and analysis
5 Completed A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide ISA-51 in Patients With Cancer.
Conditions: Cancer;   Neoplasm
Intervention: Biological: NY-ESO-1b peptide plus CpG 7909 and Montanide ISA-51
6 Not yet recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: DEC-205/NY-ESO-1 fusion protein CDX-1401;   Drug: poly ICLC;   Drug: IDO1 inhibitor INCB024360
7 Completed Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: fowlpox-NY-ESO-1 vaccine;   Biological: recombinant vaccinia-NY-ESO-1 vaccine;   Procedure: adjuvant therapy
8 Completed Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: NY-ESO-1 peptide vaccine;   Biological: incomplete Freund's adjuvant
9 Withdrawn Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Primary Peritoneal Cavity Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Primary Peritoneal Cavity Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IC Primary Peritoneal Cavity Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Primary Peritoneal Cavity Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Primary Peritoneal Cavity Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Primary Peritoneal Cavity Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine;   Drug: IDO1 inhibitor INCB024360;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Completed Vaccine Therapy in Treating Patients With Transitional Cell Cancer of the Bladder
Condition: Bladder Cancer
Interventions: Biological: BCG vaccine;   Biological: NY-ESO-1 peptide vaccine;   Biological: sargramostim
11 Recruiting CT Antigen TCR-Engineered T Cells for Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Treatment with NY-ESO-1c259-modified T cells
12 Completed Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine;   Biological: sargramostim
13 Completed Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer
Condition: Pathologically Demonstrated Bladder Cancer
Intervention: Other: Data acquisition and analysis
14 Terminated A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma
Condition: Synovial Sarcoma
Intervention: Drug: Anti-CTLA4 (monoclonal antibody MDX-010)

Indicates status has not been verified in more than two years